Victory Capital Management Inc. Buys 149,699 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Victory Capital Management Inc. grew its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 70.9% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 360,829 shares of the company's stock after purchasing an additional 149,699 shares during the quarter. Victory Capital Management Inc. owned about 0.12% of Amneal Pharmaceuticals worth $3,024,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in AMRX. Janney Montgomery Scott LLC grew its position in shares of Amneal Pharmaceuticals by 26.9% in the 1st quarter. Janney Montgomery Scott LLC now owns 19,350 shares of the company's stock valued at $162,000 after acquiring an additional 4,100 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in Amneal Pharmaceuticals by 53.4% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 60,567 shares of the company's stock valued at $508,000 after purchasing an additional 21,079 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Amneal Pharmaceuticals by 45.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 318,420 shares of the company's stock worth $2,522,000 after purchasing an additional 99,866 shares during the period. California State Teachers Retirement System increased its position in Amneal Pharmaceuticals by 10.3% during the fourth quarter. California State Teachers Retirement System now owns 131,713 shares of the company's stock worth $1,043,000 after buying an additional 12,282 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its position in Amneal Pharmaceuticals by 209.2% during the fourth quarter. BNP Paribas Financial Markets now owns 168,194 shares of the company's stock worth $1,332,000 after buying an additional 113,796 shares during the last quarter. Institutional investors own 31.82% of the company's stock.

Amneal Pharmaceuticals Price Performance

Shares of NASDAQ:AMRX opened at $8.06 on Monday. Amneal Pharmaceuticals, Inc. has a one year low of $6.50 and a one year high of $9.48. The company has a market cap of $2.53 billion, a price-to-earnings ratio of -201.45 and a beta of 1.06. The firm has a 50 day simple moving average of $7.87 and a 200 day simple moving average of $7.96.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last announced its quarterly earnings results on Friday, May 2nd. The company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.05. Amneal Pharmaceuticals had a negative net margin of 0.46% and a negative return on equity of 188.26%. The company had revenue of $695.42 million during the quarter, compared to the consensus estimate of $714.78 million. As a group, analysts expect that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Wall Street Zen downgraded Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, May 13th. The Goldman Sachs Group initiated coverage on Amneal Pharmaceuticals in a report on Friday, June 6th. They set a "buy" rating and a $12.00 price target for the company. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $11.60.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.